ArticlePloS one2025
Lifetime prevalence of cancer in Germany between 2010 and 2019: An analysis based on aggregated data.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany cancer survivors (i.e., individuals alive who have been diagnosed with cancer at some point in their lives) remain under surveillance by doctors and medical professionals regardless of the outcome of their treatment as they face the risk of recurrence and/or encounter symptoms and other health-related issues. With advancements in cancer early detection, diagnostics, and treatment strategies, along with an increasingly older population, the number of cancer survivors is steadily increasing. Since information on epidemiological indicators of cancer survivors is limited in Germany, the present study aims to estimate its prevalence between 2010 and 2019.
methodsThe annual age- and sex-specific lifetime prevalence of cancer was estimated using a partial differential equation. The calculation was based on comprehensive data obtained from the Centre for Cancer Registry Data (Zentrum für Krebsregisterdaten, ZfKD), the Central Research Institute of Ambulatory Health Care in Germany (Zentralinstitut für die kassenärztliche Versorgung, Zi), and the German Federal Statistical Office.
resultsOur estimates indicate a rise in lifetime prevalence of cancer between 2010 and 2019 across all ages up to 85, particularly pronounced among older individuals. By 2019, the highest prevalence was estimated to be 49% of males and 28% of females at age 85. In contrast, childhood cancer was relatively rare, affecting less than 0.3% of girls and boys until the age of 18. Generally, the prevalence of cancer was higher among males than females. Overall, the number of cancer survivors aged up to 85 was estimated to increase from 2.51 million in 2010 to over 5.07 million in 2019.
conclusionsThe findings indicate a substantial rise in the lifetime prevalence of cancer in 2019 compared to 2010. Considering a cancer patient as cured based on a specific timeframe may lead to an underestimation of the future demand for healthcare resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.